Matthew L. Posard is Director of Talis Biomedical Corp. Currently has a direct ownership of 62,500 shares of TLIS, which is worth approximately $111,875. The most recent transaction as insider was on Feb 17, 2021, when has been sold 62,500 shares (Common Stock) at a price of $16.0 per share, resulting in proceeds of $1,000,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 62.5K
0% 3M change
0% 12M change
Total Value Held $111,875

Matthew L. Posard Transaction History

Date Transaction Value Shares Traded Shares Held Form
Feb 17 2021
BUY
Open market or private purchase
$1,000,000 $16.0 p/Share
62,500 Added 50.0%
62,500 Common Stock

Also insider at

DMTK
DermTech, Inc. Healthcare
HALO
HALOZYME THERAPEUTICS, INC. Healthcare
NAUT
Nautilus Biotechnology, Inc. Healthcare
MLP

Matthew L. Posard

Director
San Diego, CA

Track Institutional and Insider Activities on TLIS

Follow Talis Biomedical Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TLIS shares.

Notify only if

Insider Trading

Get notified when an Talis Biomedical Corp insider buys or sells TLIS shares.

Notify only if

News

Receive news related to Talis Biomedical Corp

Track Activities on TLIS